Large Cap

Lockheed Martin Does Not Alter Annual Outlook To Price Tariff Impact Yet Amid Recent CFO Change
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
ManpowerGroup Must Beware Of Tariff Overhang Despite EU Upside: JPMorgan
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer
ManpowerGroup Must Beware Of Tariff Overhang Despite EU Upside: JPMorgan
Wall Street Sinks, Dollar Slides As Trump Ramps Up Fed Attacks: What's Driving Markets Monday?
Gold Price Soars To Record Highs, Eyes Best 2-Month Rally Since 2011 On Blockbuster ETF Buying

Large Cap Recent News

3M Stock Surges After Q1 Beat As 2025 Outlook Flags Tariff Pressure
3M Company (MMM) stock surged on better-than-expected Q1 2025 results, with net sales of $5.95B, adjusted net sales of $5.8B, and adjusted EPS of $1.88.
Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'
Danaher posted Q1 revenue of $5.74 billion and EPS of $1.88, both above estimates, with bioprocessing and diagnostics driving better-than-expected results.
BofA Sees Tariff Impact As Minimal On GE Vernova Ahead Of Earnings
GE Vernova is set to report Q1 earnings, with analysts watching for guidance reaffirmation, hydrogen turbine updates, and tariff impact insights.
Why Roblox's Q1 Has BofA Analyst Optimistic For Long-Term Prospects, Despite Investor Sentiment Split About Growth
Buy rating maintained on Roblox with $79 price forecast. Analyst expects company to gain market share in video game sector and exceed expectations.
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use
Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty
Amazon shares have fallen nearly 25% in 2025 and the stock is taking another blow on Monday after an analyst slashed its price target. 
Chevron & TotalEnergies Fire Up Ballymore: Deepwater Gulf Project Targeting 150 Million Barrels Over Life
Chevron has started production from Ballymore project in the Gulf of Mexico. It is expected to deliver 75,000 barrels/day and marks Chevron's first in the Norphlet trend.
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.
Trump Administration Fast-Tracks Ten Domestic Critical Mineral Projects
US to accelerate 10 critical mineral production projects under FAST-41 program to reduce reliance on foreign imports. Enhanced coordination with centralized dashboard aims to shorten lengthy permitting processes and strengthen domestic supply chains.
These Large Cap Tech And Healthcare Stocks Had A Poor Run In Easter Week (Apr 14-Apr 18): Are These In Your Portfolio?
Large-cap stocks had poor performance last week, including UnitedHealth Group, Global Payments, Applovin, Humana, DaVita, Meta Platforms, Yum China, CoreWeave, Burlington Stores, Super Micro Computer, and GlobalFoundries.
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Consumer Tech News (Apr 14-Apr 18): Trump's 125% China Tariff Sidesteps Consumer Tech, Tesla Model Y Spotted in India & More
Trump excludes China-made tech products from tariffs, reducing scope of levies. Tesla's Musk and Meta's Zuckerberg voice clips hacked in California. Rivian boasts US-centric supply chain.
Trump Blasts Powell, Nvidia Tumbles On New Export Ban, Gold Defies Gravity: This Week In Markets
Wall Street ended Easter week red due to US-China chip export restrictions, mixed earnings, and trade tensions. Fed hints at no rate cuts.

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved